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relation (Spearman’s and Pearson’s coefficient range 0.74–
0.92 and 0.73–0.93, respectively) was noted for the pairwise 
comparison of antibodies by observer and of observers by 
antibody. The inter- and intraobserver reproducibility of the 
Ki-67 score classification into equal quarters (1–25, 26–50, 
51–75 and 76–100%) or into 3 categories with cutoffs at 15 
and 30% was fair to poor in the middle categories, but mod-
erate to substantial in the low and high ranges. Interobserv-
er differences in practice potentially impacted on less con-
sistent classification.  Conclusion: Our results indicate that 
the three different Ki-67 antibodies tested do not substan-
tially influence the reproducibility of the estimated prolifera-
tion rates. Although reproducibility is better in the clinically 
more relevant distinction of high versus low proliferation, 
without standardization, the current practice of Ki-67 assess-
ment in many laboratories does not allow proper and con-
sistent therapeutic decision-making. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Proliferation is an important feature of malignant
tumors including breast cancer  [1–4] . Various methods 
have been established for its quantification, including mi-
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 Abstract 
 Objective: The Ki-67 proliferation index has received an im-
portant role in treatment tailoring and molecular classifica-
tion of estrogen receptor-positive breast carcinomas. The 
aim was to analyze the reproducibility of assessing prolifera-
tion on the basis of Ki-67 immunohistochemistry.  Methods: 
Thirty core biopsy samples of breast cancer patients were 
analyzed after immunostaining with B56, SP6 and MIB-1 
monoclonal Ki-67 antibodies. All samples were evaluated 
twice and independently by 3 pathologists, with each ob-
server performing his daily routine practice. The ratio of Ki-
67-positive cells was estimated with 5% accuracy. Correla-
tion was calculated for the results of each investigator for all 
pairs of antibodies and for the results of each antibody for all 
pairs of investigators. Ki-67 scores were divided into catego-
ries of either 4 quarters or into 3 groups reflecting the St. 
Gallen consensus recommendations with 15 and 30% as cut-
off values. The reproducibility of classifying the tumors into 
these categories was assessed with   statistics.  Results: Al-
together, 540 evaluations were made. Good to excellent cor-
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totic index counting, measurement of S-phase fraction by 
flow cytometry, counting of argyrophilic nucleolar orga-
nizer regions, positron emission tomography and immu-
nohistochemistry of proliferation-associated antigens. 
Beresford et al.  [4] have highlighted the limitations of 
many of these new methods and have suggested Ki-67 
immunohistochemistry to be the standard proliferation 
assay due to its simplicity and wide availability. Ki-67 is 
a nuclear protein present in all stages of the cell cycle ex-
cept G0  [5] . The anti-Ki-67 antibody labeling index (LI, 
percentage of nuclear antigen-positive cells) has been 
proposed as a prognostic and predictive marker for breast 
cancer, especially for estrogen receptor (ER)-positive, 
HER2-negative early breast carcinoma  [1, 6–8] . Different 
studies have demonstrated that a high Ki-67 LI indicates 
an increased risk of recurrence  [7, 9, 10] , metastasis  [7–9, 
11–15] and faster progression of the disease. Some publi-
cations emphasize that adding chemotherapy to endo-
crine therapy is a recommended treatment in this popu-
lation of patients  [15] . Different cutoff values of Ki-67 LI 
have been proposed for the indication of chemotherapy 
for these patients  [9, 12, 16–18] . Owing to the relevance of 
this factor in recommending the addition of chemother-
apy, the reproducibility of Ki-67 LI evaluation is highly 
important.
 With Ki-67 immunohistochemistry, proliferating tu-
mor cells show nuclear positivity, and pathologists pro-
vide the percentage of cells with nuclear immunostain-
ing (Ki-67 LI). This relatively subjective evaluation of
Ki-67 LI can lead to a high degree of interobserver vari-
ability, e.g., there are pathologists who estimate the per-
centage of nuclear staining, whereas others count the 
number of positive cells in different fields of the tumor 
area  [1, 19] . Besides such methodological differences, 
there are other factors including tissue fixation, hetero-
geneity of staining in different tumor areas (e.g., periph-
ery vs. central part), heterogeneity of nuclear labeling in-
tensity (according to the variation of the amount of pro-
tein during the cell cycle) and human or technical 
performance that also generate interobserver variability. 
Although a Ki-67 LI cutoff value was defined at the St. 
Gallen International Expert Consensus on the Primary 
Therapy of Early Breast Cancer for recommending adju-
vant chemotherapy in endocrine-responsive breast car-
cinomas  [20–22] , there are no standardized methods to 
eliminate the different influential factors mentioned 
above. In this study, we analyzed the reproducibility of 
the Ki-67 expression levels by types of antibody and in-
vestigator method in core biopsy samples of breast can-
cer patients.
 Materials and Methods 
 Patients and Samples 
 Core biopsy samples of patients with operable T2  6 3 cm or 
T3–4 and/or N1–2 and M0 breast cancer candidates for neoadju-
vant docetaxel-epirubicin with/without capecitabine chemother-
apy were retrospectively analyzed  [23] . Samples had been taken
between January 2003 and December 2011 at the Department of 
Radiology, University of Szeged, or at the Bács-Kiskun County 
Teaching Hospital. The tumor samples were fixed in buffered for-
malin and embedded in paraffin. Samples have been routinely 
stained with hematoxylin and eosin and routinely immunostained 
for ER, progesterone receptor, HER-2 and topoisomerase II  . For 
the purpose of this study, they were immunostained for Ki-67 with 
the following 3 antibodies: SP6 (monoclonal rabbit antibody; Hisz-
topatologia Kft., Pécs, Hungary), B56 (monoclonal mouse anti-
body; Hisztopatologia Kft.) and MIB-1 (monoclonal mouse anti-
body; Dako, Glostrup, Denmark) ( fig. 1 ). Wet antigen retrieval con-
sisted of pretreatment of all samples in a microwave oven in a citrate 
buffer with pH 6 for 30, 30 and 50 min in the case of MIB-1, B56 
and SP6, respectively. All antibodies were diluted at 1: 100. Expres-
sion of Ki-67 was determined using Dako EnVision FLEX/HRP, 
DAB+ Chromogen (Dako). In the present study, all samples were 
assessed independently by 3 pathologists at high-power magnifica-
tion ( ! 400). The ratio of Ki-67-positive cells was estimated with 5% 
accuracy; therefore, only values ending with 5 or 0 were recorded. 
Each observer was asked to use his daily evaluation approach to 
quantify the proportion of Ki-67-positive cells and to perform the 
evaluation of all cases stained with one antibody first, followed by 
all cases stained with the second and third antibody, in order to 
avoid bias arising from remembering the LI of a given sample. The 
assessments were done twice with an interval of at least 2 months.
 The results of each investigator were analyzed for all pairs of 
antibodies, and the results of the different antibodies were ana-
lyzed for all pairs of investigators. To assess how the parameters 
correlate with each other, Spearman’s rank correlation was used 
in these pairwise analyses. Similarly, assuming an ideal linear re-
lationship between Ki-67 LI values, Pearson’s coefficients were 
calculated for the same pairs. To further investigate the influence 
of the observers and the antibody on the Ki-67 LI value, two-way 
ANOVA was performed. The computations were done with the 
statistical software package SPSS 15.0 for Windows (SPSS Inc., 
Chicago, Ill., USA).
 Ki-67 scores were divided into four quarters (0–25, 26–50, 51–
75 and 76–100% Ki-67 LI) to allow categorical data analyses. Four 
equally sized categories were arbitrarily chosen to limit their 
number and to allow a better analysis of the consistency of rating 
into a given category. As the 15% limit has been proposed as a cut-
off for the low proliferation category and the 30% limit as a cutoff 
for the high proliferative category, grouping according to these 
two marginal values (into 3 categories of unequal size) was also 
evaluated. Interobserver, interreagent and intraobserver agree-
ments were assessed with   statistics according to Fleiss  [24] . In-
terobserver reproducibility was also evaluated by determining 
pairwise weighted   values  [24] . These weighted   values do not 
only take into account the classification into another category 
(non-agreement) but also give weight to the ‘distance’ between the 
ordinal categories that have been used for classifying the Ki-67 
values (e.g., having two ratings in neighboring categories is better 
than having them in categories separated by another category). 
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The   values were interpreted as reflecting slight (0–0.2), fair 
(0.21–0.4), moderate (0.41–0.6), substantial (0.61–0.8) and almost 
perfect ( 1 0.8) agreement between observations according to Lan-
dis and Koch  [25] .
 Results 
 Thirty core biopsy samples of breast cancer patients 
were analyzed. The mean age  8 SE of the population was 
46  8 2 years (range 26–70). Samples included 28 invasive 
ductal carcinomas and 2 invasive lobular carcinomas. Al-
together, 270 evaluations were made by 3 independent pa-
thologists with expertise in breast pathology (G.C., A.V. 
and E.C.), and these were repeated a second time to better 
assess intraobserver variability. Mean  8 SE Ki-67 LI val-
ues of the first and the second evaluations by the 3 pa-
thologists were 45  8 2, 52  8 2 and 56  8 2% for the SP6, 
B56 and MIB-1 antibodies, respectively.
 Spearman’s rank correlation was used for compari-
son of the different observers and antibodies. Each anal-
a b c
d e f
g h i
j k l
 Fig. 1. Examples of tumor samples belonging to each quarter category (1–25%,  a–c ; 25–50%,  d–f ; 51–75%,  g–i ; 
76–100%,  j–l ) of Ki-67-positive cells on the basis of majority opinion, immunostained with the 3 different Ki-67 
antibodies (SP6,  a ,  d ,  g ,  j ; B56,  b ,  e ,  h ,  k ; MIB1,  c ,  f ,  i ,  l ).  ! 20. 
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ysis was performed on the first and the second evalua-
tion separately and then combined. Interobserver com-
parisons for the dual (combined) evaluation suggested 
that the correlation between ratings was good to excel-
lent (coefficients ranging between 0.74 and 0.91; p  ! 
0.0001). Interantibody comparisons yielded coefficients 
ranging between 0.8 and 0.92 (p  ! 0.0001), suggesting 
excellent interantibody correlation. Pearson’s coeffi-
cients ranged from 0.73 to 0.91 (p  ! 0.0001) for observer 
pairs and from 0.79 to 0.93 (p  ! 0.0001) for antibody 
pairs, suggesting similarly good to excellent correlation. 
When all 18 ratings (3 observers, 3 antibodies, twice) of 
the 30 cases were considered, allocation of the cases de-
termined by the majority was as follows: 1st quarter (0–
25% Ki-67 LI), 5 cases; 2nd quarter, 12 cases; 3rd quar-
ter, 6 cases; 4th quarter, 7 cases. Only 2 tumors had all 
ratings falling into the same quarter: 1 belonging to the 
lowest and 1 to the highest proliferation group. For oth-
er categorization, the majority of classifications suggest-
ed that 3 cases had a Ki-67 LI  ^  15%, 4 cases fell into the 
16–30% LI category, and 23 cases had a high prolifera-
tion, with an LI  1 30%. All 10 cases with a 100% agree-
ment in the classification belonged to the highly prolif-
erative tumors.
 On the basis of the   values, the reproducibility of the 
Ki-67 LI values by quarter category distribution was gen-
erally moderate to substantial in the lowest and the high-
est ends, but was only slight to fair in the middle quarter 
categories ( table 1 a). This resulted in overall   values re-
flecting only fair reproducibility both for given observers 
and for given antibodies. The same statement can be 
made after the evaluation of the dual assessment of all 
cases with all antibodies (18 evaluations per case). Pair-
wise weighted   values showed somewhat better
interobserver consistency (range 0.43–0.75), reflecting 
moderate to substantial reproducibility. When looking at 
the distributions determined by the 15 and 30% cutoff 
values, the reproducibility of the highly proliferative clas-
sification remained moderate/substantial, but the low 
and intermediate proliferation groups were less repro-
ducible ( table 1 b). Pairwise weighted   values ranged be-
tween 0.3 and 0.78 for these categories and also suggested 
fair to substantial reproducibility. The better reproduc-
ibility reflected by the weighted   values indicates that 
inconsistent categorizations were often one category 
away from each other, i.e., low proliferation rates were 
unlikely to be ranked as high and vice versa.
 Similar statements can be made concerning the in-
traobserver agreements determined for all 90 immuno-
stained samples ( table 2 ): tumors with a high and a low 
Table 2.   values reflecting intraobserver reproducibility of the 
classification of Ki-67 LIs into 4 or 3 categories
a    Quarter categories
0–25% 26–50% 51–75% 76–100% Overall
Observer 1 0.76 0.34 0.13 0.51 0.42
Observer 2 0.4 0.01 0 0.61 0.26
Observer 3 0.55 0.32 0.3 0.51 0.41
b    Categories determined by cutoff values
<16% 16–30% >30% Overall
Observer 1 0.64 0.5 0.69 0.61
Observer 2 0.37 0.07 0.57 0.36
Observer 3 0.45 0.32 0.64 0.5
Table 1.   values per observer and antibody according to classifi-
cation into four quarters categories and into 3 categories deter-
mined by 2 cutoff values
a    Quarter categories
0–25% 26–50% 51–75% 76–100% Overall
All1 0.47 0.24 0.14 0.52 0.34
Observer 1 0.63 0.32 0.15 0.51 0.39
Observer 2 0.45 0.13 0.03 0.54 0.3
Observer 3 0.58 0.38 0.28 0.55 0.44
MIB-1 0.51 0.24 0.15 0.54 0.36
B56 0.48 0.27 0.11 0.52 0.35
SP6 0.44 0.2 0.15 0.57 0.32
b    Categories determined by cutoff values
0–15% 16–30%       >30% Overall
All1 0.42 0.19 0.52 0.39
Observer 1 0.61 0.38 0.61 0.52
Observer 2 0.42 0.13 0.51 0.37
Observer 3 0.4 0.24 0.54 0.41
MIB-1 0.35 0.26 0.56 0.41
B56 0.38 0.1 0.53 0.37
SP6 0.45 0.29 0.56 0.44
1  All refers to the 18 assessments of the same cases with 3 an-
tibodies, by 3 observers, twice. The remaining values are based on 
6 assessments each: for the observers, 3 antibodies, twice; for the 
antibodies, 3 observers, twice.
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Ki-67 LI can be more reproducibly identified than tu-
mors falling into the intermediate (26–75 or 16–30%) 
range both on the basis of the quarter-based 4-tiered dis-
tribution or the two cutoffs defined by 3-tiered dis-
tribution. However, differences between observers can 
also be identified. Observer 2 demonstrated a somewhat 
worse performance than the other 2 observers: he had 
only 47% identical categorizations on a quarter basis (in 
contrast to 57 and 58% for the 2 other observers) and 63% 
identical categorizations on the basis of the 3-tiered clas-
sification (in contrast to 80 and 83% for the 2 other ob-
servers).
 Two-way ANOVA has confirmed the fact that observ-
er 2 rated the cases significantly lower than the other 2 
observers (p = 0.004 for first observations and p = 0.008 
for second observations) and also suggested that one an-
tibody (SP6) resulted in significantly lower mean Ki-67 
LI values (45.2% overall vs. 52.3% for B56 and 55.7% for 
MIB-1; p = 0.017 for first-round observations and p = 0.01 
for second-round observations).
 The individual evaluation patterns were also evaluat-
ed. It turned out that all observers aimed to quantify the 
area with the highest number of stained cells; very weak-
ly, faintly staining nuclei were generally discarded. All 
observers estimated the proportion of positive cells in re-
lation to approximately 100 tumor cells of the chosen 
area, but there were also differences in the way of estimat-
ing this proportion. Observer 1 counted 100 cells and re-
counted the number of positive nuclei in the same 100 
cells. Care was taken to keep in mind the tumor struc-
tures included and excluded in the 100-cell-containing 
area to allow the count of the positive nuclei in the same 
100 cells. Observer 2 counted 10 tumor cells to get an im-
pression of the area these cells occupied and included an 
area of tumor cells 10 times greater than this basic count, 
and finally, effectively counted the number of positive 
nuclei in the area estimated to contain 100 tumor cells. 
Observer 3 made an approaching guess in a larger area of 
the hot spot, then counted the proportion of stained nu-
clei in 20 or 30 cells and multiplied it by 4 or 3 to get a 
percentage estimate. For cases with a very high LI, a re-
verse count was made by evaluating the unstained nuclei. 
Therefore, the used methods were comparable in some 
respects, but differed in their details of cell counting. All 
were generally based on different approximations of the 
proportion of nuclear staining in relation to 100 cancer 
cells in hot spot areas and neither tried to better estimate 
this ratio by counting 1,000 cells as suggested by some 
authors  [8, 26] .
 Discussion 
 Proliferation has been proposed as an important prog-
nosticator of breast carcinomas, and the Ki-67 LI has 
been implied as a factor enabling a distinction between 
tumors with a high and a low proliferation. In this re-
spect, Ki-67 has been used in various settings including 
the addition of adjuvant chemotherapy to hormonal ther-
apy for hormone-sensitive breast carcinomas (St. Gallen 
International Expert Consensus on the Primary Therapy 
of Early Breast Cancer, 2009), the distinction of luminal 
A and luminal B subsets of ER-positive and HER-2 nega-
tive carcinomas  [26] or the distinction between histolog-
ical grade 2 carcinomas with an outcome similar to grade 
1 or grade 3 cancers  [27] .
 The present study suggests that the correlation be-
tween assessments by different observers or using differ-
ent antibodies is good or excellent, but that interobserver 
reproducibility of the Ki-67 LI may only be fair in every-
day pathology practice. This may cast some doubt on the 
general usefulness of this marker in its present state.
 The data also suggest that the classification of tumors 
into low and high proliferation categories is better (mod-
erate to substantial) than that of tumors with an interme-
diate proliferative activity. This proved true both for cut-
offs of 25 and 75% (per equal quarters assessment) and 
for cutoffs at 15 and 30% as proposed by the St. Gallen 
Expert Consensus  [20] . This may also mean that the 
range where the distinction is clinically important is 
characterized by better reproducibility.
 We also noted a rather consistent intraobserver repro-
ducibility variation. The   values relating to observer 2 
were consistently lower than the values of the other 2 ob-
servers, although the high and low proliferation catego-
ries had higher   values even for this observer. This may 
reflect the differences in the technique of evaluating the 
Ki-67 LI. All observers made the LI estimation on the ba-
sis of approximately 100 cells in a hot spot area. Observer 
1 counted real percentage values by counting 100 cells 
and recounting the positive (or at times the negative) nu-
clei in the same cells. Observer 2 approximated the area 
containing 100 cells by first delineating an area with one 
tenth of this population and then counted the positive 
tumor cell nuclei in this area. Finally, observer 3 counted 
the proportion of immunostained tumor cell nuclei in 
one fifth or one third of the area and then extrapolated 
this result to 100 cells. The two latter techniques spare 
time. Interestingly, observer 3 had   values very compa-
rable with those of observer 1. The most ‘time-consum-
ing’ evaluation, that of observer 1, took 3–4 min per case 
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and 90–100 min for scoring the 30 cases in the series 
once.
 MIB-1 is generally used in everyday practice to deter-
mine the Ki-67 LI on formalin-fixed and paraffin-em-
bedded material. This antibody was generated using
recombinant technology and reacts with the immuno-
dominant area of the Ki-67 nuclear antigen  [28] . B56 is 
directed against the same area and also represent an
immunoglobulin G1 mouse monoclonal antibody. Al-
though SP6 is a rabbit monoclonal antibody directed 
against the C terminus of the Ki-67 protein, it has recent-
ly been reported to correlate well with MIB-1 staining 
 [29] . SP6 showed significantly lower mean Ki-67 LI values 
in both the first- and the second-round assessments than 
the other antibodies, but this did not influence reproduc-
ibility. In keeping with the above, the 3 antibodies used 
had very similar overall   values reflecting fair to moder-
ate reproducibility for the whole range of the cases. Again, 
reproducibility of classifying the cases into a low and a 
high proliferation category according to either cutoffs 
tested was better than classifying the cases into ‘grey 
zone’ intermediate categories.
 It is also important to highlight that our findings were 
retrieved on core biopsy samples. Core biopsies might not 
always contain 1,000 tumor cells for counting, as non-
tumor tissue may be a common part of such specimens. 
Of the different factors potentially influencing the Ki-67 
LI, tissue fixation, heterogeneity of different tumor areas 
and heterogeneity of nuclear labeling intensity are infre-
quent in such small samples, and this may improve repro-
ducibility, although, on the other hand, the representative 
nature of a small sample may be questionable. For exam-
ple, Romero et al.  [30] showed significant differences be-
tween core biopsy and surgical sample proliferation val-
ues, which may confirm our assumption that core biopsy 
specimens allow better reproducibility on the basis of a 
smaller sample with lesser variability.
 This is not the first study to look at the reproducibility 
of the Ki-67 LI. Several other studies casted doubts on
the reproducibility of Ki-67 LI evaluation  [1, 19, 30] . Al-
though the St. Gallen International Expert Consensus on 
the Primary Therapy of Early Breast Cancer (2009 and 
2011) recommended an accurate methodical proceeding 
(e.g., counting 1,000 tumor cells), the everyday use and 
ability to follow this recommendation is questionable. As 
suggested in the present series, even intralaboratory dif-
ferences in assessment may exist (pathologists may tend 
to use less time-consuming methods). Despite only fair 
overall reproducibility of the Ki-67 LI into categories of 
different proliferative activity, the results between the ob-
servers and the antibodies were at least moderately cor-
related, and the identification of tumors with the highest 
proliferation was better (moderate to substantial) than 
that of tumors with intermediate proliferation according 
to both approaches tested (although this is the result of a 
universal statistical occurrence, we should be more aware 
of this phenomenon in clinical decision making and ac-
knowledge that intermediate or ‘grey-zone’ categories are 
generally less reproducible than low- and high-value cat-
egories, as exemplified by our data). Therefore, it seems 
that clinically important categorizations (high vs. non-
high proliferation) can be more consistently made even 
with the methods described, although it is believed that 
substantial to excellent reproducibility would make the 
use of Ki-67 as a biomarker more confident. The histo-
logical grade of breast carcinomas is also a potential fac-
tor that may affect therapeutic decisions, but grading was 
not much better reproducible among expert breast pa-
thologists, with overall   values ranging from 0.43 to 
0.59, and grade 2 tumors being less reproducibly classi-
fied as such than grade 1 or grade 3 tumors  [31] . Further-
more, although Ki-67 LI has been reported as a potential 
tool to discriminate between grade 2 tumors of better and 
worse prognosis  [27] , the reproducibility of Ki-67 LI in 
this group of tumors was recently found to be inconsis-
tently reproducible  [32] . Even those things that seem easy, 
like identifying breast carcinomas with 90–100% stain-
ing for ERs, may seem suboptimally reproducible on the 
basis of   values: the consistency among expert breast pa-
thologists was not much better with a   value of 0.52, al-
though finding a good cutoff (10% at that time) allowed 
excellent reproducibility of categorizing the tumors into 
negative versus positive  [33] .
 In conclusion, our results suggest that reproducibility 
of the Ki-67 LI is less than optimal even in core biopsies 
of breast cancer patients. However, the reproducibility of 
classifying tumors into a clinically more important high-
ly proliferative category (like  1 15,  1 25 or  1 30%) is better 
than that of the overall classification and is not dependent 
on the antibody used (at least true for the 3 antibodies 
tested). At present, the consistency of Ki-67 LI determi-
nation in the routine work of some (probably numerous) 
laboratories (including ours) does not allow error-free 
therapeutic decision making on a yes or no basis. Our re-
sults also indicate that similar but slightly differing indi-
vidual practices of Ki-67 LI evaluation by different ob-
servers may influence reproducibility, and therefore, rea-
sonable standardization and the recommendation of a 
workable uniform method should be encouraged.
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